Related references
Note: Only part of the references are listed.Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease
Ruth-Anne Langan Pai et al.
JCI INSIGHT (2020)
Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease Study protocol for clinical trial
Tomohiro Koga et al.
MEDICINE (2020)
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease
David C. Fajgenbaum et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan
Shino Fujimoto et al.
MODERN RHEUMATOLOGY (2018)
Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012)
Hiroshi Kawabata et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2013)
Share Paper
